Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Glioblastoma 154Brain Neoplasms 73Glioma 69Central Nervous System Neoplasms 50Gliosarcoma 46Astrocytoma 37Melanoma 36Oligodendroglioma 29Neuroblastoma 17Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 11Sarcoma, Ewing 10Sarcoma 10Neoplasms 10Medulloblastoma 10Recurrence 9Neuroendocrine Tumors 9Lymphoma 8Ependymoma 8Breast Neoplasms 8Small Cell Lung Carcinoma 7Rhabdomyosarcoma 7Diffuse Intrinsic Pontine Glioma 7Colorectal Neoplasms 7Carcinoma, Neuroendocrine 6Adenoma, Islet Cell 6Uveal Melanoma 5Spinal Cord Neoplasms 5Pheochromocytoma 5

Interventions

Thalidomide 1Temozolomide 1Tegafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Extrapancreatic Neuroendocrine Tumor × Temozolomide × Clear all
NCT03204032 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Extrapancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡